Enrollment halted as researchers study safety signal

Potential safety issues have prompted Forest Laboratories and its development partner, Germany's Paion, to halt enrolling patients in a late-stage trial of a compound that mimics a protein found in bat saliva. The independent monitoring committee says they want time to analyze more of the data from the drug, desmoteplase, to evaluate a "safety signal." No other details were provided. Desmoteplase is a clot-dissolving protein intended as a treatment for stroke.

- see the release on the trial

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.